c-RET
Los inhibidores de c-RET se dirigen al protooncogén RET (Rearranged during Transfection), que codifica una tirosina quinasa receptora involucrada en el crecimiento, diferenciación y supervivencia celular. La activación anormal de la señalización de RET puede llevar a una proliferación celular descontrolada y resistencia a la apoptosis, contribuyendo al desarrollo de cánceres como el carcinoma medular de tiroides y el cáncer de pulmón de células no pequeñas. Inhibir c-RET puede inducir apoptosis en células cancerosas y es un enfoque prometedor en la terapia contra el cáncer dirigida. En CymitQuimica, ofrecemos una variedad de inhibidores de c-RET de alta calidad para apoyar su investigación en oncología, transducción de señales y apoptosis.
Se han encontrado 51 productos de "c-RET"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS:<p>BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.</p>Fórmula:C23H27F4N3O4SPureza:99.23%Forma y color:SolidPeso molecular:517.54RET Ligand-Linker Conjugate-1
<p>RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.</p>Fórmula:C40H44N10OForma y color:SolidPeso molecular:680.84RET ligand-1
CAS:<p>RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.</p>Fórmula:C28H24F2N6O3Forma y color:SolidPeso molecular:530.525RET-IN-26
<p>RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].</p>Forma y color:Odour SolidAD57 (hydrochloride)
CAS:<p>AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.</p>Fórmula:C22H21ClF3N7OPureza:98%Forma y color:SolidPeso molecular:491.9YW-N-7 TFA
<p>YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.</p>Fórmula:C58H63F3N12O9Forma y color:SolidPeso molecular:1129.19RET ligand-3
<p>RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.</p>Fórmula:C38H42N10O3Forma y color:SolidPeso molecular:686.81RET-IN-28
CAS:<p>RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.</p>Fórmula:C26H29N9Forma y color:SolidPeso molecular:467.57Zeteletinib hemiadipate
CAS:<p>Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.</p>Fórmula:C56H56F6N8O12Forma y color:SolidPeso molecular:1147.098PLM-101
<p>PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.</p>Fórmula:C22H22FN5O2Forma y color:SolidPeso molecular:407.44RET-IN-4
CAS:<p>RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.</p>Fórmula:C27H31FN10O2Forma y color:SolidPeso molecular:546.611BT44
CAS:<p>BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.</p>Fórmula:C28H27F4N3O4SPureza:99.87%Forma y color:SoildPeso molecular:577.59Compound TPX-0046
CAS:<p>Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.</p>Fórmula:C21H21FN6O3Pureza:99.94%Forma y color:SoildPeso molecular:424.43QZ2135
<p>QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.</p>Fórmula:C53H54N12O4Forma y color:SolidPeso molecular:923.07trans-Pralsetinib
CAS:<p>trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).</p>Fórmula:C27H32FN9O2Pureza:98%Forma y color:SolidPeso molecular:533.6TPX-0046
CAS:<p>TPX-0046 is a RET inhibitor designed to overcome resistance to Selpercatinib and Pralsetinib.</p>Fórmula:C21H21FN6O3Pureza:99.95%Forma y color:SolidPeso molecular:424.43Pralsetinib
CAS:<p>Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T</p>Fórmula:C27H32FN9O2Pureza:97.88% - 99.8%Forma y color:SolidPeso molecular:533.6WHI-P180
CAS:<p>WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.</p>Fórmula:C16H15N3O3Pureza:99.21%Forma y color:SolidPeso molecular:297.31Treprostinil Sodium
CAS:<p>Treprostinil Sodium (UT-15) is a potent DP1, IP and EP2 agonist (EC50: 0.6/1.9/6.2 nM).</p>Fórmula:C23H33NaO5Pureza:99.67% - >99.99%Forma y color:SolidPeso molecular:412.5GSK3179106
CAS:<p>GSK3179106 is RET kinase inhibitor with an IC50 of 0.4 nM</p>Fórmula:C22H21F4N3O4Pureza:99.8% - 99.90%Forma y color:SolidPeso molecular:467.41Selpercatinib
CAS:<p>"Selpercatinib (LOXO-292) is a RET tyrosine kinase inhibitor with IC50s of 14.0, 24.1, 530.7 nM for different RET mutations."</p>Fórmula:C29H31N7O3Pureza:99.89% - >99.99%Forma y color:SolidPeso molecular:525.6Pyrazoloadenine
CAS:<p>Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.</p>Fórmula:C5H5N5Pureza:99.02%Forma y color:Beige PowderPeso molecular:135.13BBT594
CAS:<p>BBT594 (NVP-BBT594)(NVP-BBT594) is a potent inhibitor of receptor tyrosine kinase RET,Treatment of cancer.</p>Fórmula:C28H30F3N7O3Pureza:99.57%Forma y color:SolidPeso molecular:569.58SPP-86
CAS:<p>SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.</p>Fórmula:C16H15N5Pureza:99.53%Forma y color:SolidPeso molecular:277.32RET V804M-IN-1
CAS:<p>RET V804M-IN-1 (RETV804M kinase inhibitor) is a wt-RET -selective RETV804M kinase inhibitors(IC50 = 20 nM).</p>Fórmula:C19H16N6OPureza:97.94% - 99.62%Forma y color:SolidPeso molecular:344.37WHI-P180 hydrochloride
CAS:<p>WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.</p>Fórmula:C16H16ClN3O3Forma y color:SolidPeso molecular:333.77RET-IN-22
CAS:<p>RET-IN-22 (compound 17b) is a potent, selective, and orally active inhibitor of RET, exhibiting IC50 values of 20.9 nM for wild-type RET and 18.3 nM for RET-</p>Fórmula:C29H31F3N6O4Forma y color:SolidPeso molecular:584.59RET-IN-15
CAS:<p>RET-IN-15 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.</p>Fórmula:C27H28N8O2Forma y color:SolidPeso molecular:496.56RET-IN-6
CAS:<p>RET-IN-6 is a potent inhibitor of RET (IC50: 4.57 nM).</p>Fórmula:C30H29N7Forma y color:SolidPeso molecular:487.6DUN73423
CAS:<p>DUN73423 (RET-IN-21) is a potent tyrosine kinase (RET) inhibitor with antitumour activity for the study of cancer.</p>Fórmula:C19H16N6OPureza:98.09%Forma y color:SolidPeso molecular:344.37RET-IN-8
CAS:<p>RET-IN-8 is an inhibitor of rearrangement kinase (RET) during transfection and can be used in cancer research.</p>Fórmula:C27H30N6O3Forma y color:SolidPeso molecular:486.57TRK II-IN-1
CAS:<p>TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.</p>Fórmula:C29H31F3N8OPureza:98%Forma y color:SolidPeso molecular:564.6RET-IN-16
CAS:<p>RET-IN-16: Selective RET inhibitor, IC50s 3.98-15.05 nM for various RET mutations; anticancer properties.</p>Fórmula:C31H29F3N8O2Forma y color:SolidPeso molecular:602.61RET-IN-12
CAS:<p>RET-IN-12 is a RET inhibitor capable of acting on RET(WT) (IC50: 0.3 nM) and RET(V804M) (IC50: 1 nM).</p>Fórmula:C30H30F3N5O4Forma y color:SolidPeso molecular:581.59RET-IN-23
CAS:<p>RET-IN-23 is an orally available and highly potent RET inhibitor with significant antitumor activity for the study of non-small cell lung cancer.</p>Fórmula:C28H28FN11Pureza:97.46%Forma y color:SolidPeso molecular:537.59RET-IN-3
CAS:<p>RET-IN-3 is a RETV804M kinase inhibitor with potential anticancer activity for the study of non-small cell lung cancer.</p>Fórmula:C18H21N5O2Pureza:99.52%Forma y color:SolidPeso molecular:339.39RET-IN-25
CAS:<p>RET-IN-25 (compound 6b) is an anticancer RET kinase inhibitor that demonstrates efficacy against medullary thyroid carcinoma (MTC), exhibiting half-maximal</p>Fórmula:C22H17N3O5SForma y color:SolidPeso molecular:435.45RET-IN-17
CAS:<p>RET-IN-17 inhibits RET kinase; may help in IBS pain and RET-activated cancers.</p>Fórmula:C27H28F4N4O4Forma y color:SolidPeso molecular:548.53Vepafestinib
CAS:<p>Vepafestinib is a RET inhibitor with potential antineoplastic activity[1].</p>Fórmula:C26H30N6O3Pureza:98.56%Forma y color:SolidPeso molecular:474.55RET-IN-24
CAS:<p>RET-IN-24 (Compound 26) is a selective inhibitor of RET tyrosine kinase, demonstrating antitumor activity [1].</p>Fórmula:C27H26F2N8OForma y color:SolidPeso molecular:516.55RET-IN-5
CAS:<p>RET-IN-5 is a potent inhibitor of RET (IC50: 4.57 nM).</p>Fórmula:C29H26FN9OForma y color:SolidPeso molecular:535.57FHND5071
CAS:<p>FHND5071, a potent and selective RET kinase inhibitor, exerts antitumor effects through the inhibition of RET autophosphorylation and may be utilized for tumor</p>Fórmula:C30H30D3N9OForma y color:SolidPeso molecular:538.66NSC194598
CAS:<p>NSC194598 is a p53 DNA-binding inhibitor, demonstrating an in vitro IC50 of 180 nM and an in vivo range of 2-40 μM.</p>Fórmula:C20H19N3OForma y color:SolidPeso molecular:317.38FLT3/ITD-IN-4
CAS:<p>FLT3/ITD-IN-4 inhibits FLT3-ITD mutations in acute myeloid leukemia (IC50: 2.3 nM).</p>Fórmula:C25H22N4O5Forma y color:SolidPeso molecular:458.47RET-IN-13
CAS:<p>RET-IN-13: potent quinoline RET inhibitor; IC50 = 0.5 nM (WT), 0.9 nM (V804M); potential for RET-related tumor/intestinal disease research.</p>Fórmula:C32H33F4N5O3Forma y color:SolidPeso molecular:611.63RET-IN-10
CAS:<p>RET-IN-10: Potent RET inhibitor, may treat congenital megacolon and tumors (Patent WO2021135938A1, compound 18).</p>Fórmula:C29H28N8OSForma y color:SolidPeso molecular:536.65RET-IN-7
CAS:<p>RET-IN-7 exhibits strong inhibitory effects against RET kinase in vitro and shows significant efficacy in treating RET-driven tumor xenografts in mice through</p>Fórmula:C22H24ClFN6O2Forma y color:SolidPeso molecular:458.92RET-IN-1
CAS:<p>RET-IN-1 is a RET kinase inhibitor (IC50s: 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively).</p>Fórmula:C29H31N9O3Pureza:98%Forma y color:SolidPeso molecular:553.61WF-47-JS03
<p>WF-47-JS03: RET kinase inhibitor, crosses blood-brain barrier, 500x more selective for KDR, IC50: 1.7 nM in Ba/F3 cells, 5.3 nM in LC-2/ad lung cancer cells.</p>Fórmula:C30H38N6O2Forma y color:SolidPeso molecular:514.66RET-IN-9
CAS:<p>RET-IN-9 is a potent RET kinase inhibitor, potentially useful for studying RET-related diseases, including lung and thyroid cancer.</p>Fórmula:C26H27N9OForma y color:SolidPeso molecular:481.55Enbezotinib
CAS:<p>Enbezotinib is an inhibitor of RET autophosphorylation and can be used in cancer research.</p>Fórmula:C21H21FN6O3Pureza:99.84%Forma y color:SolidPeso molecular:424.43
